Search research articles
Contact Us
Filters
Showing results (51-60 of 602) with videos related to
Page
of 61
Sort By:
Experimental Neurology
|
November 29, 2005
Morris water maze search strategy analysis in PDAPP mice before and after experimental traumatic brain injury
David L Brody, David M Holtzman
Annual Review of Neuroscience
|
March 21, 2008
Active and passive immunotherapy for neurodegenerative disorders
David L Brody, David M Holtzman
Neuron
|
December 11, 2012
Stealth attack: plaque-specific antibody allows for efficient Aβ removal without side effects
Jee Hoon Roh, David M Holtzman
Science (New York, N.Y.)
|
November 26, 2016
Mechanisms linking circadian clocks, sleep, and neurodegeneration
Erik S Musiek, David M Holtzman
Experimental Neurology
|
September 6, 2003
Differential metabolism of ApoE isoforms in plasma and CSF
Suzanne E Wahrle, David M Holtzman
Alzheimer Disease and Associated Disorders
|
June 15, 2006
Amyloid-beta immunotherapies in mice and men
Robert P Brendza, David M Holtzman
Neuron
|
September 15, 2021
Effects of COVID-19 on preclinical and clinical research in neurology: Examples from research on neurodegeneration and Alzheimer's disease
B Joy Snider, David M Holtzman
The Journal of Clinical Investigation
|
July 1, 2025
Thwarting amyloidosis: IL-17 as a disease modifier along the gut/brain axis
Wade K Self, David M Holtzman
Experimental & Molecular Medicine
|
January 3, 2024
Current understanding of the Alzheimer's disease-associated microbiome and therapeutic strategies
Dong-Oh Seo, David M Holtzman
Annals of Neurology
|
February 2, 2019
Reply to "obstructive sleep apnea treatment and amyloid-β in cerebrospinal fluid"
Yo-El S Ju, David M Holtzman
Page
of 61
Search research articles
Search
Showing results (51-60 of 602) with videos related to
Sort By:
Page
of 61
Experimental Neurology
|
November 29, 2005
Morris water maze search strategy analysis in PDAPP mice before and after experimental traumatic brain injury
David L Brody, David M Holtzman
Annual Review of Neuroscience
|
March 21, 2008
Active and passive immunotherapy for neurodegenerative disorders
David L Brody, David M Holtzman
Neuron
|
December 11, 2012
Stealth attack: plaque-specific antibody allows for efficient Aβ removal without side effects
Jee Hoon Roh, David M Holtzman
Science (New York, N.Y.)
|
November 26, 2016
Mechanisms linking circadian clocks, sleep, and neurodegeneration
Erik S Musiek, David M Holtzman
Experimental Neurology
|
September 6, 2003
Differential metabolism of ApoE isoforms in plasma and CSF
Suzanne E Wahrle, David M Holtzman
Alzheimer Disease and Associated Disorders
|
June 15, 2006
Amyloid-beta immunotherapies in mice and men
Robert P Brendza, David M Holtzman
Neuron
|
September 15, 2021
Effects of COVID-19 on preclinical and clinical research in neurology: Examples from research on neurodegeneration and Alzheimer's disease
B Joy Snider, David M Holtzman
The Journal of Clinical Investigation
|
July 1, 2025
Thwarting amyloidosis: IL-17 as a disease modifier along the gut/brain axis
Wade K Self, David M Holtzman
Experimental & Molecular Medicine
|
January 3, 2024
Current understanding of the Alzheimer's disease-associated microbiome and therapeutic strategies
Dong-Oh Seo, David M Holtzman
Annals of Neurology
|
February 2, 2019
Reply to "obstructive sleep apnea treatment and amyloid-β in cerebrospinal fluid"
Yo-El S Ju, David M Holtzman
Page
of 61